


January 28-31

# 2021 *Virtual* SNMMI MID-WINTER AND ACNM ANNUAL MEETING

# PREVIEWMAGAZINE

[WWW.SNMMI.ORG/MWMPREVIEW](http://WWW.SNMMI.ORG/MWMPREVIEW)



2021  
Mid-Winter  
Meeting

ACNM  
ANNUAL MEETING

# FOURSIGHT

CREATING A NEW VISION FOR PROSTATE CANCER IMAGING



When it comes to prostate cancer imaging, accurate detection lies in the details.<sup>1</sup> And you can't treat what you can't detect. Using optimal technology, targets, tracers, and tools such as **PET, PSMA, <sup>18</sup>F, and AI systems** could improve diagnostic performance and help pave the way for more informed prostate cancer treatment decisions.<sup>1-5</sup>

**We are investigating ways to take imaging to the next level.**  
**Learn how at [FoursightProstateCancer.com](https://FoursightProstateCancer.com)**

**Progenics**  
Pharmaceuticals®

 **Lantheus**  
Holdings

**References:** **1.** Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? *Ther Adv Oncol.* 2019;11:1-14. doi.org/10.1177/1758835919876828 **2.** Petersen L, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer; an expedited systematic review. *Cancer Imaging.* 2020;1-8. doi:10.1186/s40644-202-0290-9 **3.** Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus <sup>18</sup>F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. *Radiology.* 2020;296:44-55. doi.org/10.1148/radiol.2020191689 **4.** Zippel C, Ronski SC, Bohnet-Joschko S, Giesel FL, Kopka K. Current status of PSMA-radiotracers for prostate cancer: data analysis of prospective trials listed on clinicaltrials.gov. *Pharmaceuticals.* 2020;1-13. doi:10.3390/ph13010012 **5.** Data on file. Progenics Pharmaceuticals, Inc.

Trademarks, registered or otherwise, are the property of their respective owners.

© 2020 Lantheus Holdings, Inc. All rights reserved. PM-US-PY-0033



# Virtual Presentation. Real-World Results.

**SNMMI and ACNM are excited to welcome you virtually to the 2021 SNMMI Mid-Winter and ACNM Annual Meeting.**

Over 3.5 days, you'll experience a virtual platform that incorporates both the intimate format and collaborative environment you've come to expect from the meeting, with a dynamic, virtual attendee experience that (almost) makes you forget you're not meeting in person!

The meeting will feature three educational tracks highlighting the latest innovations and techniques in the field. Scientific sessions, industry-led satellite symposiums, and technologist-focused programming are also available, providing you with a comprehensive learning opportunity!

Best of all, since the meeting is being held virtually, you have the flexibility to experience the entire meeting from the comfort and safety of your home or office, when it's convenient for you.

**The 2021 Virtual SNMMI Mid-Winter and ACNM Annual Meeting lets you:**

## ✔ **Watch Sessions When/Where it's Convenient for You**

Watch sessions live as they happen. The sessions will feature live chat functionality during live broadcasts of the presentations. Miss a session? **Each session will be available for on-demand viewing following its live broadcast for 30 days.** Plus, as a registered attendee, you'll get access to additional technologist-focused programming taking place February 2-6.

## ✔ **View Leading Research in Dedicated Science Pavilion**

View **abstract presentations and posters of the profession's latest research**, including recorded oral presentations from the authors. You will also be able to ask the authors questions by emailing them while visiting their poster/ abstract.

## ✔ **Interact with Industry Suppliers in the Virtual Exhibit Hall**

Visit **30 customized virtual booths from top suppliers** and learn more about their products/services through videos and downloadable presentations. Plus, connect one-on-one with exhibit personnel while visiting their booth through direct text and video chat.

## ✔ **Re-Connect with Colleagues and Luminaries during Innovative Networking Opportunities**


Interact with fellow attendees through one-on-one and group chat, and during great networking events, highlighted by the **ACNM Awards Ceremony**. During this marquee event, ACNM will honor its 2021 Lifetime Achievement Award Winner; 2021 Gold Medal Award winner; present the ACNM Abstract Awards; and induct its 2021 Class of Fellows

## THANK YOU TO OUR TITLE SPONSOR

We would like to recognize our title sponsor, Advanced Accelerator Applications, a Novartis Company, for their generous support of the 2021 Virtual SNMMI Mid-Winter and ACNM Annual Meeting.



**Earn up to 27.5 continuing education credits.**



# WELCOME MESSAGE

On behalf of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Scientific Program Committee, I would like to welcome you to the Virtual 2021 SNMMI Mid-Winter and ACNM Annual Meeting.

As we continue to navigate this unprecedented time, I would like to sincerely thank the many planners of this year's meeting – the SNMMI Scientific Program Committee, SNMMI's Councils and Centers of Excellence, the SNMMI Technologist Section, and the American College of Nuclear Medicine (ACNM). Despite all the personal and professional challenges that everyone is facing, they have once again collaborated to plan a truly exceptional meeting.

This year our focused track will be on therapy. This track will showcase both cutting-edge research and development in this area as well as the practical clinical application of therapies. This content will cover the latest on therapies for prostate cancer, NETs, thyroid, and pediatric patients. We would like to thank the Therapy Center of Excellence for their many efforts in planning this informative track.

There will also be a General Nuclear Medicine Track offering a variety of timely topics:

- Investing in Inclusion: Why and How
- Hot Topics in Nuclear Cardiology 2020: Case Based Review
- COVID-19: Effects on Clinical Care and Education
- Artificial Intelligence in Nuclear Medicine
- Molecular Brain Imaging and the ATN Framework
- Pediatric Nuclear Medicine Applications: Common to Obscure

In addition to the content offered over the 3.5 days of the meeting, participants will be able to attend exclusive supplemental content in the days following the meeting. There will be a week of content planned by the Technologist Section as well as additional General Nuclear Medicine Track sessions. If you are registered for the Mid-Winter Meeting, you will automatically be registered for these supplemental sessions in February and March.

This year's meeting will also offer six educational Satellite Symposia delivered by our industry partners. I would encourage you to participate in these informative sessions. I would also like to sincerely thank this year's exhibitors and sponsors for their contributions to making this meeting a success. Make sure you take the time to visit the Exhibit Hall. Industry representatives will be in the Exhibit Hall throughout the meeting to showcase their latest offerings and answer your questions.

And finally, there will be several networking opportunities in the evenings that you won't want to miss. While we can't be together in person, we can still enjoy a sense of community through these virtual networking events.

We hope you enjoy the meeting!

Best wishes,



Umar Mahmood, MD, PhD  
Chair, SNMMI Scientific Program Committee

# WELCOME MESSAGE

## FROM THE ACNM PROGRAM COMMITTEE

It is our pleasure to welcome you to the "COVID free" 2021 ACNM Virtual Annual Meeting held in conjunction with the SNMMI Mid-Winter Meeting. This year, we are bringing the "The Latest and Greatest of Nuclear Medicine" to your private screens.

The ACNM is proud to showcase the research of young professionals. The ACNM Research Abstract Oral Presentations will be held on **Thursday** afternoon. Please log in and support the future of our profession. This year we are extending the award categories to recognize physics and new technological innovations' abstracts. Selected virtual presentations will be nominated and awarded by a panel of judges. The winners will be announced in the virtual ACNM Awards Ceremony and Banquet on Friday night.

The ACNM 2020 President, Dr. Yang Lu, will open the educational program on Friday morning, followed by expert panel sessions of "The latest and greatest " theranostics, development, clinical use of Breast PET FES, and the impact of genetics on thyroid cancer management. For the recognition of women in nuclear medicine, we have invited women nuclear medicine physicians to discuss the clinical outcome of PRRT for neuroendocrine tumors in the Asian population, the change in the imaging paradigm in prostate cancer in India, and the theranostic use of radionanomedicine in South Korea. The day will be concluded with a case-based SAM session discussing the topics presented throughout the day. In this meeting, we will offer both CME and SAM credits.

This year the **Mandell-Alavi Plenary** lecture session will take place on Friday from 11:45 am-1:15 pm ET. The plenary lecture, generously endowed by Drs. Gerald Mandell and Abass Alavi, supports a keynote speaker who has had an extraordinary influence on the advancement of nuclear medicine. This year with great honor, the Mandell-Alavi Plenary lecture will be given by **Dr. John A. Katzenellenbogen** from the University of Illinois. Dr. Katzenellenbogen is recognized for contributing to the development of novel hormone-regulated PET imaging agents <sup>18</sup>F-Estrogen (FES) receptors in breast cancers and <sup>18</sup>F-androgen (FDHT) receptors in prostate cancers.

The annual **ACNM Awards Ceremony** will be held virtually. As every year, we are honored to invite you for a social evening of networking and with colleagues. At the banquet, we will announce ACNM's annual awards, including the 2021 ACNM Fellows' election and the recognition of this year's Gold Medal, Lifetime Achievement, Best Mentor, and Abstract Awards. In addition, we are excited to announce an international recital performance for our talent show; the singer Eva (Xiaohua) Zhu and Vivian (Boxianzi) Ling, a violinist from the San Francisco Symphony. In addition, members of ACNM's leadership team, Dr. Twyla Bartel and Dr. Tracy Yarbrough will take the virtual stage for a duet. And as an added treat for the evening, we are delighted to have Brennan Ayres, the son of Dr. Karen Ayres, entertain us with a special piano solo.

We are excited to see you at our annual meeting virtually. If you are not already, we hope you will join us as an [ACNM member](#)

Sincerely,

ACNM Program Committee

Bitat Savir-Baruch, MD, Chair of the 2021 ACNM Program Committee

Mariam Aboian, MD, Ph.D.

Alan Klitzke, MD, Ph.D. FACNM

Bruce Barron, MD, FACNM

Twyla Bartel, DO, MBA, FACNM

Simin Dadparvar, MD, FACNM, FACR

Gary Ulaner, MD, Ph.D., FACNM

Yang Lu, MD, Ph.D., FACNM

Sean Xuexian Yan, MD

## ACNM Meeting Reviewers

Gholam Berenji, MD, FACNM

Fani Bozkurt, MD

Patrick Colletti, MD

David Brandon, MD

Simin Dadparvar, MD, FACNM, FACR

Rakesh Kumar, MD, PhD

Jagurti Shah, MD

Jian (Michael) Q. Yu, MD, FRCPC, FACNM

Hongming Zhuang, MD, PhD

## ORAL Presentations

Thursday, January 28, 2021

2:30-4:30 pm (Oral Session #1)

Oral Presentations will be given in the order below.

Each presentation will be 8 minutes with 2 minutes for questions.

### Oral Session #1

#### Golmehar Sistani

The Efficacy of <sup>177</sup>Lu-Dotatate Induction and Maintenance Therapy in the Treatment of Various Types of Neuroendocrine Tumours with Variable Dose: Phase II Registry Study  
(oral #1)

#### Ida Sonni

Head-to-Head comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and MP-MRI in the Detection, Intra-Prostatic Localization and Local Extension of Primary Prostate Cancer: A Single-Center Imaging Study with Histopathology Gold-Standard  
(oral #2)

#### Ashanth Thomas

Every Breath Counts: A Novel Application of Quantitative Lung with SPECT/CT to Evaluate the Efficacy of BLVR  
(oral #3)

#### Syed Bukhari

Development and Validation of a Diagnostic Model and Clinical Score to Predict a Positive Tc-99m Pyrophosphate Scintigraphy : A Pilot Study  
(oral #4)

#### Ashwin Parihar

<sup>68</sup>Ga-Dota-Exendin PET/CT versus Contrast Enhanced Computed Tomography in Patients with Hyperinsulinemic Hypoglycaemia  
(oral #5)

#### Reyhaneh Manafi-Farid

Five-year Biochemical Recurrence-Free Survival Following Radionuclide-Guided Super-Extended Versus Standard Extended Pelvic Lymphadenectomy in Patients with Clinically Localized Prostate Cancer  
(oral #6)

#### David Cardoza-Ochoa

Frequency of Pitfalls and Detection Efficacy of <sup>18</sup>F-PSMA-1007 PET/CT in Patients with Biochemically recurrent Prostate Cancer  
(oral #7)

#### Sara Pacella

Predictive Role of <sup>18</sup>F-FDG PET/CT in Alzheimer's Disease  
(oral #8)

### Oral Session #1

#### Susan Shafiei

Different Dose Strategies for Radioiodine Therapy of Patients with Graves' disease, A Clinical Trial  
(oral #9)

#### Sara Shakeri

Evaluation of the Role of <sup>68</sup>Ga-PSMA PET/CT Scanning in Patients with High Risk Prostate Cancer  
(oral #10)

#### Sonya Youngju Park

Pilot Study Evaluating the Role of Novel PSMA Ligand <sup>18</sup>F-Florastamin PET/CT in Men with Clinical Suspicion of Prostate Cancer  
(oral #11)

#### Reyhaneh Manafi-Farid

Prognostic Value of <sup>18</sup>F FDG PET-CT in Metastatic Melanoma Patients Receiving Immunotherapy  
(oral #12)



# ORAL Presentations

Thursday, January 28, 2021  
4:45-6:45pm (Oral Session #2)

Oral Presentations will be given in the order below.  
Each presentation will be 8 minutes with 2 minutes for questions.

## Oral Session #2

### TMengshi Li

Pb-212  $\alpha$ -Particle Radiotherapy Induces Immunogenic Cell Death and Synergistic anti-Tumor Effect in Combination with Immunotherapies  
(oral #1)

### Najme Karamzade-Ziarati

Impact of TSH Stimulation on 18F FDG PET/CT Results in Patients with Papillary Thyroid Carcinoma Presented with Elevated Serum Thyroglobulin Level and Negative Diagnostic 131sup Whole-Body Scan  
(oral #2)

### Heying Duan

Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma from a Single Institution Experience  
(oral #3)

### Maithaa El-Dakhely

The Relation between Bone Marrow Uptake in Baseline 18F-FDG-PET/CT and Bone Marrow Biopsy in Patients with Diffuse Large B Cell Lymphoma  
(oral #4)

### Jad El Bulbul

Ongoing Androgen Deprivation Therapy in Patients with Biochemical Recurrent Prostate Cancer Does Not Influence the Positivity Rate of 18F-Fluciclovine PET/CT Scan  
(oral #5)

### Jad El Bulbul

Positivity Rate of 18F-Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence and Low PSA Values of < 1 ng/mL  
(oral #6)

### Damian Grybowski

The Role of 18F-Fluciclovine PET/CT Scan in the Identification of Patients with Oligometastatic Prostate Cancer  
(oral #7)

### Edgar Zamora

Best Practices in Nuclear Medicine Training in the Era of COVID-19 - An Integrated Software-Based Approach to Remaining Academically Connected While Physically Dispersed  
(oral #8)

### Arun Kumar

Experience with a Perfusion-Only Screening Protocol for Evaluation of Pulmonary Embolism During the COVID-19 Pandemic Surge  
(oral #9)

### Patrick Earl Fernando

A Comparative Study of Different Methods of Estimating Glomerular Filtration Rate in a Subset of Filipinos with Normal Renal Function  
(oral #10)

### Heying Duan

Peptide Receptor Radionuclide Therapy (PRRT) in Non-Midgut Neuroendocrine Tumors (NETs) from a Single Institution Experience  
(oral #11)

### Nicholas DiSanti

99mTc-MAA SPECT/CT Measuring Reperfusion Following Acute Pulmonary Embolism: Is Anticoagulation Superior to Reperfusion Therapy  
(oral #12)

# Poster Presentations

## Science Pavilion

January 28-January 31, 2021

Poster Number	Abstract Title	Presenting Author
1	Exercise Myocardial Perfusion Imaging And Transient Ischemic Dilation: An Angiographic Correlative Study	Besher Sadat
2	Efficacy, Safety and Prognostic Factors Affecting Overall Survival among Metastatic Prostate Cancer Patients Undergoing Treatment with <sup>177</sup> Lu-PSMA-617: A Single Center Study from Iran	Soroush Zarehparvar
3	Quantitative Assessment of Asphericity as a New Predictor of Adverse Outcome in Patients with Neuroblastoma	Mikhail Yadgarov
4	Characterization of Radioactive Citrate Uptake in Hepatocellular Carcinoma	Seon Yoo Kim
5	Assessment of Motor Dysfunction with Virtual Reality in Patients Undergoing I-123 Ioflupane SPECT/CT Imaging	Jeanne Vu
6	Correlation of Pre-Operative Sonographic Tumor Size with Pathologic Findings in Patients with Thyroid Carcinoma	Somaye Barashki
7	A Novel Method for Accurate Quantification of Split Glomerular Filtration Rate Using Combination of <sup>99m</sup> Tc-DTPA SPECT and its Plasma Clearance	Xiaoxi Pang
8	Oncologic Significance of Incidental Osseous Foci on FDG-PET Without Correlative CT Abnormalities	Edgar Zamora
9	<sup>68</sup> GA-Dotatate PET/CT Referrals for Elevated Chromogranin-A	Edgar Zamora
10	Repeat Injection Following Sentinel Node Non-Visualization on Lymphoscintigraphy Images Can Decrease Axillary Dissection Rate in Breast Cancer Patients	Atena Aghaee
11	Prognostication of Bone Marrow Uptake in Baseline <sup>18</sup> F-FDG-PET/CT in Diffuse Large B Cell Lymphoma Patients	Maithaa El-Dakhely
12	Diagnostic Performance of Clinical <sup>18</sup> F-Fluciclovine PET/CT Scan in Recurrent Prostate Cancer	Damian J. Grybowski
13	Comparison of Half-Time Oatmeal Gastric Emptying Using Linear and Exponential Curves In Symptomatic Patients	Gbenga A. Shogbesan
14	Low dose <sup>18</sup> F- FDG PET/CT Brain Scan Versus Standard Dose in Patients with Dementia	Merzia Subhan
15	A Novel Approach Using FDG PET/CT Based Radiomics to Assess tumor Immune Phenotypes in Patients with Non-Small Cell Lung Cancer	Jianyuan Zhou
16	Diagnostic role of <sup>18</sup> F FDG PET/CT in Differentiating Pericardial Benign and Malignant Disease	Rang Wang
17	Gallium <sup>68</sup> DOTANOC in Neuroendocrine Tumors: An Institutional Review	Tehreem Zafar
18	Rate of Reported Orbital Metastases from Neuroendocrine Tumors During <sup>68</sup> Gallium-DOTATATE PET/CT Imaging	Ethan Y. Lin
19	Imaging Yttrium 90 Utilizing 3d Time of Flight PET/CT Following Trans Arterial Radioembolization: Overcoming Low Quality Bremsstrahlung Images.	Harkanwar Gill
20	An Evaluation of Nuclear Radiology Fellowship Websites in the United States	Tushar Garg
21	Noise-Signal Trade-Off In Maximum Likelihood Estimation	Dacian V. Bonta
22	Attr Amyloidosis	Kush Shah
23	Tc <sup>99m</sup> -Oxetate Scan in Differentiated Thyroid Cancer Patients with Negative Whole Body Iodine Scan, a Low Cost but Relatively Effective Method	Atena Aghaee
24	Incidental Findings on Tc <sup>99m</sup> Labelled Radionuclide Renal Scans and to Highlight the Utility of Flow Images	Jitesh Dhingra
25	Lutathera Spill: Are We Prepared on What Happens Then and What Happens Next!!	Jitesh Dhingra
26	Usage of Non-Negative Matrix Factorization in the Differentiation of Invasive and Normal Breast Tissue in Mice	Valerie Kobzarenko
27	F18 FDG PET-CT in Hepatocellular Carcinoma: Institutional Experience from Pakistan	Myda Muzaffar
28	Factors Predicting Biochemical Response and Survival Benefits Following Radioligand Therapy with [ <sup>177</sup> Lu]Lu-PSMA in Metastatic Castrate-Resistant Prostate Cancer: A Review	Reyhaneh Manafi-Farid
29	Nuclear Medicine Practice During COVID-19 Pandemic in Japan	Asami KITAOKA
30	Brain ECD-SPECT/CT: Transient Antiphospholipid Stroke-Like Presentation of COVID-19	Kwang J. Chun



# ACNM AWARD WINNERS



## 2021 Gold Medal Award

The ACNM Gold Medal recognizes individuals who have made exceptional contributions to the field of nuclear medicine and molecular imaging. The 2020 winner is: **Jay Harolds, MD, FSNMMI**



## 2021 Lifetime Achievement Award

Each year, the ACNM presents the Lifetime Achievement Award to an individual who has demonstrated an outstanding level of dedication to the ACNM and the field of Nuclear Medicine. The 2020 winner is: **Twyla Bartel, DO, MBA, FACNM**

## 2021 ACNM Fellows

Fellowship status in ACNM is awarded for recognition of significant and sustained service to the college and to the nuclear medicine community. It is with great honor that we acknowledge the following individuals as the 2019 ACNM Fellows:



**Carina Aparici, MD**



**Karen Ayres, MD**



**Joseph Osborne, MD, PhD**



**Jing Wang, MD, PhD**



**Xiaohua Zhu, MD, PhD**



**Katherine Zukotynski,  
MD, PhD, FRCPC, PEng**



## \*ACNM Personal Best Mentor

The Personal Best Mentor is reserved for those who selflessly devote their time with amiability, demeanor, and dedication to mentoring nuclear medicine professionals for leading a productive personal and professional life. The winner of the 2021 Personal Mentor-of-the-Year is: **Somali Gavane, MD**

*\*These ACNM grants are made possible through a gift to the Education and Research Foundation for Nuclear Medicine and Molecular Imaging's ACNM Fund.*



## ACNM Clinical Best Mentor

The Clinical Best Mentor reserved for those dedicated teachers of nuclear medicine in the most general term (including teachers of clinical and scientific basis of NM to trainees, other colleagues and the field at large). The winner of the 2021 Clinical Best Mentor-of-the-Year is: **Shahram Bonyadlou, MD**

*\*These ACNM grants are made possible through a gift to the Education and Research Foundation for Nuclear Medicine and Molecular Imaging's ACNM Fund.*

# ACNM AWARD WINNERS

## ACNM President's Awards

ACNM Presidents awards are awarded to members, fellows and staff of the college who have contributed selflessly to advance the mission of the college and the field of nuclear medicine during 2020 and helped the President of the college during the year. The ACNM President's awards are given to:



Mariam Aboian, MD, PhD



Twyla Bartel, DO,  
MBA, FACNM



Teresa Ellmer, MIS, CNMT



Somali Gavane, MD



Ben Greenspan, MD,  
FACNM, FACR, FSNMMI



Warren Janowitz, MD, JD



Saabry Osmany,  
MD, FACNM



Alan Packard, PhD



Virginia Pappas



Babak Saboury,  
MD, MPH, DABR, DABNM



Bitat Savir-Baruch, MD



Richard Wahl, MD, FACNM



Nikki Wenzel-Lamb



Franklin Wong, MD, PhD, JD



Sara Sheikhbahei,  
MD, MPH

## ACNM Editorial Fellowship Award

Sara Sheikhbahei, MD, MPH is awarded the 2021 ACNM Editorial Fellowship. The ACNM Editorial Fellowship includes a \$1,000 award and is designed to provide, a young professional in nuclear medicine, with 12 months of first-hand experience with scholarly publication and editorial processes. Dr. Sheikhbahei will spend a year under the guidance of the current Editor-in-Chief of Clinical Nuclear Medicine and will also have the opportunity to work directly with the editors of *Scanner* and *Scintillator*

The award is funded by a temporarily Restricted Gift Agreement by Patrick M. Colletti, MD, FACNM, FSNMMI for the American College of Nuclear Medicine through the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF)



John A. Katzenellenbogen,  
PhD

## 2021 Mandell-Alavi Lectureship on Advances in Molecular Imaging

Dr. John Katzenellenbogen, Swanlund Professor of Chemistry, directs a vigorous research program that spans chemistry, biology, and medical applications with a particular focus on the action of estrogens in breast cancer and androgens in prostate cancer. He is recognized internationally as pioneer in the development of novel diagnostic and therapeutic agents for the management of hormone-regulated cancers, including the PET imaging agents FES for estrogen receptors and FFNP for progesterone receptors in breast cancers, and FDHT for androgen receptor in prostate cancers that are widely used in the staging of disease and in the clinical development of novel anti-hormones. He has also assisted in the development of a PET-based hormone challenge test that images hormone-induced changes in tumor metabolism and other molecular targets that is proving highly predictive of response to endocrine therapies in breast cancer. Through his extensive work elucidating the molecular details of estrogen action in various target tissues, he has designed novel estrogens that are being actively used to elucidate estrogen actions by numerous collaborators throughout the world. He has been honored as a Member of the American Academy of Arts and Sciences and is the recipient of numerous awards from the American Chemical Society, the Endocrine Society, the Society for Nuclear Medicine, and the International Society for Radiopharmaceutical Sciences.

# ACNM ANNUAL MEETING TRACK – “THE LATEST & GREATEST”

The ACNM 2021 Annual Meeting track will feature a robust program of cutting-edge educational content and oral presentations, highlighted by John A. Katzenellenbogen, PhD, who will present the Mandell-Alavi Plenary Session. In addition, all meeting attendees are invited to attend ACNM Awards Ceremony and Banquet on Friday evening. During this event the ACNM will honor its 2021 ACNM Lifetime Achievement Award Winner, 2021 Gold Medal Award winner, present the ACNM Abstract Awards; and induct its 2021 Class of Fellows.

## ► Thursday, January 28

2:00–2:30 pm ET

---

### Opening/Welcome Session

2:30–4:30 pm ET

---

### ACNM Oral Abstract Presentations

4:45–6:45 pm ET

---

### ACNM Oral Abstract Presentations

## ► Friday, January 29

10:00–11:30 am ET

---

### ACNM's President's Session

---

*Sponsored by the ACNM*

---

Organizer: Yang Lu, MD, PhD, FACNM  
Moderator: Yang Lu, MD, PhD, FACNM

#### Session Description

This session will focus on the up-to-date research and current clinical practice of nuclear medicine.

#### Session Objectives

1. Discuss ACNM's efforts and initiatives in 2020; ACNM's vision and resolution for the years to come
2. Describe the perspectives of nuclear medicine leaders about the future of nuclear medicine, joined by live discussions
3. Examine the newly FDA approved FES PET tracer, and its impact on nuclear medicine practices

#### Presentations Include:

- ACNM in the Era of Theranostics: Stay Current and Keep Advancing  
*Yang Lu, MD, PhD, FACNM*
- Nuclear Medicine and Molecular Imaging in the Last Two Decades: Lessons Learned and Future Directions  
*Rathan Subramaniam, MD, PhD, MPH, FACNM, FSNMMI*
- PET Imaging of Estrogen Receptors in Breast Cancer  
*David A. Mankoff, MD, PhD*
- Q&A

## ► Friday, January 29

11:45 am–1:15 pm ET

---

### Mandell-Alavi Award Session

---

*Sponsored by the ACNM*

---

Organizer: Gary Ulaner, MD, PhD, FACNM;  
Bital Savir-Baruch, MD  
Moderator: Gary Ulaner, MD, PhD, FACNM

#### Session Description

This session introduces the newly approved FES PET/CT tracer in the imaging of breast cancer.

#### Session Objectives

1. Participate in the introduction of [18]F-fluoroestradiol
2. Discuss the clinical use of [18]F-fluoroestradiol
3. Describe the [18]F-fluoroestradiol effect on clinical management

#### Presentations Include:

- Introduction of FES PET/CT  
*Farrokh Dehdashti, MD*
- The Mandell-Alavi Award Lectureship: FES and FFNP PET Imaging in Breast Cancer: A Single Goal in an Ever-changing Landscape  
*John A. Katzenellenbogen, PhD*
- Q&A



# ACNM ANNUAL MEETING TRACK – “THE LATEST & GREATEST”

## ► Friday, January 29

2:15–3:45 pm ET

### Operationalizing Genetic and Molecular Characterization in the Management of Differentiated Thyroid Cancer

*Sponsored by the ACNM*

Organizer: Mark Tulchinsky, MD, FACNM, FSNMMI

Moderator: Alan Klitzke, MD, Ph.D. FACNM

#### Session Description

This session will discuss the importance of genetic mutations and thyroid cancer treatment.

#### Session Objectives

1. Discuss common practice with thyroid cancer management
2. Examine the importance of genetic mutation in the management of thyroid cancer
3. Describe targeted therapy of differentiator thyroid cancer

#### Presentations Include:

- Genomic and Molecular Principles of Theranostic Surgical Management of Differentiated Thyroid Cancer  
*Seza A. Gulec, MD, FACS, FACNM*
- Integration of Genetic Mutations into Theranostic Nuclear Medicine  
*Mark Tulchinsky, MD, FACNM, FSNMMI*
- Targeted Therapy in Thyroid Cancer: Reversal of Fortune  
*Seza A. Gulec, MD, FACS, FACNM*
- Metabolic and Molecular Characterization of Differentiated Thyroid Cancer for Thera-Nuclear Management  
*Mark Tulchinsky, MD, FACNM, FSNMMI*
- Q&A

## ► Friday, January 29

4:14–5:45 pm ET

### ACNM International Session: The Latest and Greatest Around the Globe

*Sponsored by the ACNM*

Organizer: Twyla B. Bartel, DO, MBA, FACNM

Moderator: Twyla B. Bartel, DO, MBA, FACNM

#### Session Description

This year, the ACNM would like to reaffirm its support of women in science in the annual international session. Presented will be a few topics of the latest use of nuclear medicine in their respective countries. The intended audience is for all nuclear medicine specialists.

#### Session Objectives

1. Share the experience of treating patients with peptide receptor radionuclide therapy in an Asian population
2. Demonstrate how Ga68 PSMA imaging is an invaluable tool to investigate the biological behavior of prostate cancer
3. Gain insights into the theranostic use of radionanomedicine

#### Presentations Include:

- Clinical Outcome of PRRT for Neuroendocrine Tumors in Asian Population  
*Dr. Wei Ying Tham*
- Ga68 PSMA: Changing the Imaging Paradigm in Prostate Cancer  
*Dr. Ishita Sen*
- Theranostic Use of Radionanomedicine  
*Dr. So Won Oh*
- Q&A

## ► Friday, January 29

6:00–7:30 pm ET

### Case-Based Summary and Review, Read with the Experts

*Sponsored by the ACNM*

Organizer: Bital Savir-Baruch, MD;

Tracy L. Yarbrough, MD, PhD, MAEd, FACNM;

Twyla B. Bartel, DO, MBA, FACNM

Moderator: Bital Savir-Baruch, MD;

Tracy L. Yarbrough, MD, PhD, MAEd, FACNM;

Twyla B. Bartel, DO, MBA, FACNM

#### Session Description

In this session, the speakers will present SAM formatted collection of questions written by different nuclear medicine experts.

#### Session Objectives

1. Describe the clinical use of <sup>18</sup>F-fluoroestradiol, <sup>18</sup>F-fluciclovine, <sup>68</sup>G- DOTA-TATE radiopharmaceuticals.
2. Discuss the clinical approach to theranostics with highlight to lutetium Lu 177 dotatate and I131.
3. Review radiopharmaceutical uptake patterns in oncology scans.

#### Presentations Include:

- Case-Based Summary and Review, Read with the Experts  
*Bital Savir-Baruch, MD;*  
*Tracy L. Yarbrough, MD, PhD, MAEd, FACNM;*  
*Twyla B. Bartel, DO, MBA, FACNM*
- Q&A

# THERAPY TRACK

The 2021 meeting will feature a dedicated Therapy track. This program has been carefully prepared to improve knowledge from patient care coordination and safety considerations, to treatment options and emerging technologies.

## ► SATURDAY, JANUARY 30

10:00–11:30 am ET

### **The Nuts and Bolts of IV Radiopharmaceutical Therapy Administration**

*Sponsored by the SNMMI Therapy Center of Excellence*

Organizers: Daniel Lee, MD; Yoram Baum, MD  
Moderators: Daniel Lee, MD; Tina Buehner, PhD, CNMT,  
FSNMMI-TS

#### **Session Description**

This is a practical session on the administration of therapeutic radiopharmaceuticals including 2 talks on techniques for intravenous administration (gravity and pump methods), a talk on acute/subacute complications of extravasations and a talk on room preparation, containing and addressing spills and contamination events, and patient education/radiation safety precautions

#### **Session Objectives**

1. Describe two methods of intravenous administration of radiopharmaceuticals
2. Recognize acute/subacute complications of radiopharmaceutical extravasation
3. Address spills and contamination events, as well as radiation safety precautions

#### **Presentations Include:**

- Techniques of IV Therapy Administration -The Gravity Method  
*Miranda Womack*
- Techniques of IV Therapy Administration – The Pump Method  
*James Crowley, MHA, CNMT*
- IV Therapy Administration: What Can Go Wrong? Acute and Subacute Complications of Extravasations  
*Ila Sethi, MD*
- Radiation Safety Aspects in IV Therapy Administration  
*Monica Johnson*
- Q&A

## ► SATURDAY, JANUARY 30

11:45 am–1:15 pm ET

### **Prostate Cancer PSMA Therapy**

*Sponsored by the SNMMI Therapy Center of Excellence*

Organizers: Ephraim E. Parent, MD, PhD; Daniel Lee, MD  
Moderators: Ephraim E. Parent, MD

#### **Session Description**

Multi-disciplinary discussion regarding PSMA therapy and its role regarding other hormonal and chemotherapeutic agents. Practical considerations regarding patient selection and administration will be discussed.

#### **Session Objectives**

1. Describe the role of PSMA radiotherapy for prostate cancer
2. Determine identification of ideal candidates for PSMA therapy
3. Recognize practical considerations for PSMA radiotherapy administration

#### **Presentations Include:**

- Medical Management of Prostate Cancer and the Role of PSMA Radiotherapy  
*A. Oliver Sartor, MD*
- Patient Selection and Management of PSMA Therapy  
*Phillip Kuo, MD, PhD*
- Practical Considerations of PSMA Radiotherapy Administration  
*Ayşe Tuba Kendi, MD*
- Q&A

# THERAPY TRACK

The 2021 meeting will feature a dedicated Therapy track. This program has been carefully prepared to improve knowledge from patient care coordination and safety considerations, to treatment options and emerging technologies.

## ► SATURDAY, JANUARY 30

2:15–3:45 pm ET

### **Updates on Radionuclide Therapies in Pediatrics: Current Status and Novel Applications**

*Sponsored by the SNMMI Therapy Center of Excellence and the SNMMI Pediatric Imaging Council*

Organizers: Neeta Pandit-Taskar, MD;  
Victor Seghers, MD, PhD; Steve Y. Cho, MD  
Moderators: Neeta Pandit-Taskar, MD;  
Victor Seghers, MD

#### **Session Description**

This session will provide an overview the status of MIBG therapy and explore the role of PRRT in pediatric patients. Clinical experience and trials data will be reviewed. Novel radionuclide therapy approaches, and techniques will be discussed.

#### **Session Objectives**

1. Examine the clinical indication, use and administration of MIBG therapy
2. Discuss the role of PRRT in neuroblastoma
3. Recognize novel targeting agents for treatment of pediatric tumors

#### **Presentations Include:**

- The Role of PRRT in NB  
*Jennifer E. Gains, MD*
- Thyroid Cancer – ATA Guidelines and Case Discussion  
*Adina L. Alazraki, MD*
- Novel Agents and Approaches for Treating Pediatric Tumors  
*Neeta Pandit-Taskar, MD*
- MIBG Therapies in NB  
*Susan E. Sharp, MD*
- Q&A

## ► SATURDAY, JANUARY 30

4:15–5:45 pm ET

### **Updates and Clinical Applications of PRRT for NET**

*Sponsored by the SNMMI Therapy Center of Excellence*

Organizers: Neeta Pandit-Taskar, MD; Steve Y. Cho, MD  
Moderators: Steve Y. Cho, MD; Neeta Pandit-Taskar, MD

#### **Session Description**

This session will overview specific topic discussions in molecular imaging and peptide receptor radioligand therapy (PRRT) for neuroendocrine tumors (NET), including gastroenteropancreatic (GEP), pheochromocytomas and paragangliomas. We will review current practice, case discussions and novel emerging approaches.

#### **Session Objectives**

1. List the basic principles of PRRT and its oncologic applications in NET
2. Define the current indications, contraindications, and response assessments for PRRT in GEP
3. Examine emerging PRRT applications in pheochromocytoma and paraganglioma

#### **Presentations Include:**

- Clinical Oncology Diagnosis and Treatments for NET  
*Jennifer R. Eads, MD*
- Current and Emerging Molecular Imaging and PRRT for NET  
*Grace Kong, MD*
- Current and Emerging Molecular Imaging for PRRT for Pheochromocytoma and Paraganglioma  
*Frank Lin, MD*
- Case Series on PRRT in NET (Interactive SAM Session)  
*Steve Y. Cho, MD*
- Q&A



# THERAPY TRACK

The 2021 meeting will feature a dedicated Therapy track. This program has been carefully prepared to improve knowledge from patient care coordination and safety considerations, to treatment options and emerging technologies.

## ► SATURDAY, JANUARY 30

6:00–7:30 pm ET

---

### Radioiodine Therapy for Differentiated Thyroid Cancer

---

*Sponsored by the SNMMI Therapy Center of Excellence*

---

Organizer/Moderator: Frederick D. Grant, MD

#### Session Description

Although radioiodine (I-131) therapy for thyroid cancer has been one of the mainstays of nuclear medicine practice for decades, the indications and perceived utility of this therapy continue to evolve. Speakers in this session will review the current use of radioiodine therapy from the perspective of a clinical endocrinologist, present an approach to radioiodine therapy from the perspective of a nuclear medicine physician, and discuss current thinking regarding the potential risks and late effects of radioiodine therapy.

#### Session Objectives

1. Discuss the evolving endocrinology perspective on the use of radioiodine therapy for differentiated thyroid cancer.
2. Describe the use of radioiodine (I-131) for the treatment of differentiated thyroid cancer
3. Summarize potential risks and late effects of radioiodine (I-131) therapy.

#### Presentations Include:

- The Clinical Endocrinologist's Evolving Perspective on the Use of Radioactive Iodine for Differentiated Thyroid Carcinoma  
*Erik K. Alexander, MD*
- Radioiodine (I-131) Treatment of Differentiated Thyroid Cancer: The Nuclear Medicine Perspective  
*Robert Flavell, MD, PhD*
- Potential Risks and Late Effects of Radioiodine (I-131) Therapy  
*Bennett S. Greenspan, MD, FACNM, FACR, FSNMMI*
- Q&A

# GENERAL NUCLEAR MEDICINE TRACK

The general nuclear medicine track features a wide-ranging scope of sessions developed and led by experts from SNMMI's specialty councils and centers of excellence. These sessions are designed to expand your knowledge on the latest clinical applications and best practices in the field advancing precision medicine.

## ► SUNDAY, JANUARY 31

8:45–9:45 am ET

### Special Session: SNMMI Inclusion Task Force Update

Details to come.

## ► SUNDAY, JANUARY 31

10:00–11:30 am ET

### Hot Topics in Nuclear Cardiology 2020: Case-Based Review

*Sponsored by the SNMMI Cardiovascular Council*

Organizer: Edward J. Miller, MD, PhD

Moderator: Brett W. Sperry, MD;

Marie A. Gueratty, MD, PhD

#### Session Description

Nuclear cardiology has evolved rapidly. Practitioners need to be familiar with new tracers, disease processes, and technology. This clinically oriented session for nuclear cardiology readers will utilize a practical, case-based review strategy for interpreting Tc99m PYP imaging for cardiac amyloidosis, FDG-PET for cardiac sarcoidosis, CZT and SPECT/CT cases and artifacts, and myocardial blood flow quantification from cardiac PET.

#### Session Objectives

1. Discuss the optimal methods to acquire and interpret Tc99m PYP imaging for cardiac amyloidosis, including artifacts
2. Gain expertise in the use of hybrid imaging systems and optimal approaches for the interpretation of FDG-PET for cardiac sarcoidosis
3. Develop understanding of artifacts specific to dedicated cardiac CZT SPECT cameras and SPECT/CT cameras in the interpretation of nuclear cardiology studies
4. Examine practical applications and pitfalls in the interpretation and reporting of myocardial blood flow quantification from PET

#### Presentations Include:

- Optimal Performance and Interpretation of Tc99m PYP Imaging for Cardiac amyloidosis: Perils, Pearls, and Pitfalls  
*Shivda Pandey, MD*
- The Use of Hybrid PET/CT Imaging in the Interpretation of FDG PET for Cardiac Sarcoidosis  
*Edward J. Miller, MD, PhD*
- How to Interpret and Integrate PET Myocardial Blood Flow into Clinical Reporting and Practice  
*Timothy Bateman, MD*
- Q&A

## ► SUNDAY, JANUARY 31

11:45 am–1:15 pm ET

### COVID-19: Effects on Clinical Care and Education

*Sponsored by the SNMMI Academic Council;  
SNMMI General Clinical Nuclear Medicine Council*

Organizers: Twyla Bartel, DO, MBA, FACNM;  
Lionel Zuckier, MD, MBA, FRCPC

Moderators: Erica Cohen, DO, FACNM;  
Lionel Zuckier, MD, MBA, FRCPC

#### Session Description

The COVID-19 pandemic has affected nearly all aspects of medicine. It has affected how we teach and learn via social distancing. It has also changed the physical layout of our departments, the way we interact with patients, colleagues, and trainees, and even the way we do some examinations. In addition, as a new disease, COVID-19 results in several new clinical manifestations that may be noted on nuclear medicine examinations.

The course will begin with a review of alternative and/or the best teaching methods for learning and retention, especially those that can be adapted to a remote situation, and followed by a discussion of data collected on which teaching methods have had the most positive impact during this COVID-19. We will then review multiple clinical aspects of the COVID-19 pandemic, in terms of its effects on medical care and "clinical" knowledge, and the business of medicine. We hope to present both best practices regarding COVID-19 and up-to-date clinical information. This should be of value to nuclear medicine technologists, trainees and

# GENERAL NUCLEAR MEDICINE TRACK

The general nuclear medicine track features a wide-ranging scope of sessions developed and led by experts from SNMMI's specialty councils and centers of excellence. These sessions are designed to expand your knowledge on the latest clinical applications and best practices in the field advancing precision medicine.

practicing physicians, both in primarily educational and non-educational settings

## Session Objectives

1. Review and explain different teaching methods and which work best for learning retention.
2. Discuss data gathered on teaching methods during COVID which have had a positive impact on learning while physically distancing.
3. Ensure the safe practice of nuclear medicine.
4. Recognize findings on nuclear medicine studies in patients affected by COVID-19.

## Presentations Include:

- Best Evidence-Based Teaching Methods for Learning Retention and which Can Work Well Remotely  
*Twyla Bartel, DO, MBA, FACNM*
- What Our Data Analysis Shows on Which Methods During COVID Have Most had a Positive Impact on Learning  
*Shana Elman, MD*
- Effect of COVID-19 on Nuclear Medicine Operations Including Cardiovascular Manifestations  
*Vasken Dilsizian, MD, FSNMMI*
- Non-Cardiac Manifestation of COVID-19 in the Nuclear Medicine Suite Including Safe Pulmonary Scintigraphy  
*Lionel Zuckier, MD, MBA, FRCPC*
- Q&A

## ► SUNDAY, JANUARY 31

2:15–3:45 pm ET

### Artificial Intelligence in Nuclear Medicine

*Sponsored by the SNMMI Physics,  
Instrumentation and Data Sciences Council*

Organizer: Joyita Dutta

## Session Description

This session will focus on the fundamentals of artificial intelligence (AI) and highlight recent advances in deep learning in the context of nuclear medicine imaging. Deep learning is particularly well-suited for the analysis of large and complex datasets including images. Unlike classical machine learning approaches, which rely on predetermined handcrafted features, deep learning algorithms learn features that are most meaningful

for a given task. In this session, we aim to provide both a foundational overview of AI methodology and discuss major applications of AI in nuclear medicine. The session is intended to provide the attendees with an in-depth understanding of AI tools that have the potential to significantly improve diagnosis, prognosis, and treatment response assessment, and to take a significant step toward realization of precision (personalized) medicine.

## Session Objectives

1. Describe the framework of a deep learning algorithm and how this differs from classical machine learning.
2. Examine motivations for applying machine learning and deep learning methods to radiological images, and how these may significantly improve diagnosis, prognosis, and treatment response assessment.
3. Recognize the pitfalls and challenges of, as well as solutions towards, the translation of deep learning methods to routine clinical practice

## ► SUNDAY, JANUARY 31

4:15–5:45 pm ET

### Molecular Brain Imaging and the ATN Framework

*Sponsored by the SNMMI Brain Imaging Council*

Organizer/Moderator: Karina Mosci, MD

## Session Description

Dementia is multifactorial and presents a challenge both for diagnosis and treatment. The purpose of the session is to review the paper of Molecular Imaging in the NIA-AA research framework that defines AD biologically, by neuropathologic change or biomarkers, and treats cognitive impairment as a symptom/sign of the disease rather than the definition of the disease. The session will address ATN concepts while reviewing the actual clinical applications for amyloid, Tau and FDG PET in brain imaging. The session aims to improve the skills of training and already trained professionals.

## Session Objectives

1. Examine the concept of ATN framework
2. Interpret amyloid, Tau and FDG-PET in AD
3. Discuss the potential of Molecular Imaging for personalized medicine by coding pathologic change



# GENERAL NUCLEAR MEDICINE TRACK

The general nuclear medicine track features a wide-ranging scope of sessions developed and led by experts from SNMMI's specialty councils and centers of excellence. These sessions are designed to expand your knowledge on the latest clinical applications and best practices in the field advancing precision medicine.

## **Presentations Include:**

- Amyloid PET  
*Jonathan McConathy, MD, PhD*
- Tau PET  
*Victor Villenmagne, MD*
- Neurodegeneration/ FDG-PET  
*Satoshi Minoshima, MD, PhD*
- Q&A

## ► SUNDAY, JANUARY 31

**6:00–7:30 pm ET**

---

### **Pediatric Nuclear Medicine Applications: Common to Obscure**

---

*Sponsored by the SNMMI Pediatric Imaging Council*

---

Organizers: Victor Seghers, MD, PhD

Moderators: Victor Seghers, MD, PhD; Reza Vali, MD

## **Session Description**

This session will cover basic clinical pediatric nuclear medicine techniques in the areas of GU-Cystography, GI, and Epilepsy. It will also cover more obscure clinical examinations such as Lymphangiography and CSF-scintigraphy. The intended audience is general nuclear medicine physicians and technologist who are interested in or perform some pediatric cases. This

course supports general “Nuts and Bolts” themes and are targeted for typical attendees of Mid-Winter Meetings.

## **Session Objectives**

1. Discuss common pediatric nuclear medicine applications
2. Gain insight into less common nuclear medicine applications
3. Learn about best practices (technique, imaging protocol, radiation dose) of various pediatric nuclear medicine exams

## **Presentations Include:**

- Pediatric GU Cystography  
*Tejal Mody, MD*
- Pediatric GI Applications in Nuclear Medicine  
*Zvi Bar-Sever, MD*
- Pediatric Epilepsy: Interesting Cases  
*Neha Kwatra, MD*
- Pediatric Lymphangiography  
*Marguerite T. Parisi, MD, MS Ed*
- Pediatric CSF-Scintigraphy  
*Hedieh Khalatbari, MD*
- Q&A

# SATELLITE SYMPOSIA

Hear directly from industry in these popular one-hour virtual presentations. Pre-registration is not required but encouraged to receive any pre-meeting materials from the organizing company.



## Precision Imaging for Detection and Localization of Recurrent Prostate Cancer

**FRIDAY, JANUARY 29 ▶ 1:15–2:15 PM ET**

*Sponsored by Blue Earth Diagnostics, Inc.*

**Speaker:** Munir Ghesani, MD, FACNM, FACR; Chief of Nuclear Medicine, Mount Sinai Health, NY

### Session Objectives

1. Understand the prevalence, incidence, and mortality rates associated with prostate cancer
2. Demonstrate the challenges of detecting and localizing recurrent prostate cancer using standard imaging techniques
3. Examine the diagnostic performance and value of PET/CT in detecting and localizing recurrent prostate cancer to inform clinical management plans
4. Evaluate PET/CT in clinical practice by reviewing case studies



## Role of Cerianna™ (<sup>18</sup>F Fluoroestradiol) in Breast Cancer imaging

**FRIDAY, JANUARY 29 ▶ 1:15–2:15 PM ET**

*Sponsored by Zionexa*

### Speakers:

- Dr. Robert S. Bridwell, MD, MBA, Charles Town, West-Virginia
- Dr. Hannah M. Linden, MD, Seattle Cancer Care Alliance, Washington
- Dr. Deepak Behera, MD, San Francisco, California

Dr. Bridwell reviews Cerianna's use in clinical scenarios including some case studies. Dr. Linden and Dr. Behera will have a discussion on the oncologist point of view on impact of <sup>18</sup>F Fluoroestradiol in breast cancer management. The session will conclude with a Q&A session with the speakers.



## Detectnet™ (copper Cu 64 dotatate injection) – A Novel Agent for PET Imaging of Neuroendocrine Tumors

**SATURDAY, JANUARY 30 ▶ 1:15–2:15 PM ET**

*Sponsored by Curium*

### Speakers:

- Erik Mittra, MD, PhD – Chief, Nuclear Medicine & Molecular Imaging – Oregon Health & Science University (OHSU)
- Adam Brown, BS, NMTCB (CNMT)(CT)(PET), RT(N) – Manager, Nuclear Medicine & Molecular Imaging – OHSU

Dr. Erik Mittra will present a summary of the clinical data on the use of Detectnet (copper Cu 64 dotatate injection) in Neuroendocrine Tumors (NETs), including case studies highlighting the clinical utility in various scenarios. Mr. Adam Brown will be discussing the protocol and image acquisition details. The session will conclude with a panel Q&A session, including the speakers as well as Dr. Eric Liu, a general surgeon specializing in NET patient care at the Rocky Mountain Cancer Center.

# SATELLITE SYMPOSIA

Hear directly from industry in these popular one-hour virtual presentations. Pre-registration is not required but encouraged to receive any pre-meeting materials from the organizing company.



## Expanded SPECT/CT Integration into Clinical Nuclear Medicine

**SUNDAY, JANUARY 31 ► 1:15–2:15 PM ET**

*Sponsored by Siemens Healthineers*

**Speaker:** Kathryn A. Morton, MD, Professor, Department of Radiology and Imaging Sciences. Chief, Nuclear Medicine Service University of Utah School of Medicine

The availability of high-quality SPECT/CT has greatly expanded the diagnostic value of nuclear medicine and has provided opportunities for improved therapeutic planning. SPECT/CT can be applied to almost any nuclear medicine imaging study with a resultant improvement in definitive interpretative assessment and precise anatomic relevance. The goal of the symposium is to comprehensively profile the current and potential role of SPECT/CT for many nuclear medicine applications, including those where SPECT/CT has not played a traditional role. Join us Sunday as Dr. Morton reviews her experiences using SPECT/CT in a clinically expanded role.



## Ga-68 PSMA-11: Advances in Technology, Demand & Supply | Industry Leaders' Round-Table Discussion

**SUNDAY, JANUARY 31 ► 1:15–2:15 PM ET**

*Sponsored by Telix Pharmaceuticals*

### Speakers:

- Chris Behrenbruch, CEO, Telix Pharmaceuticals (Moderator)
- Delphine Chen, MD, Director of Molecular Imaging Seattle Cancer Care Alliance University of Washington
- Jean Bonnet, Head of Strategy, Sales & Marketing, IRE
- Uno Zetterberg, Global Sales & Product Director, Cyclotrons & PET Radiopharmacy, GE Healthcare
- Serge Lyashchenko, PharmD, MSKCC

This Symposium offers perspectives from Industry Leaders on recent advances in PSMA-PET Imaging and how the radiopharmaceutical industry will meet the ever increasing demand for Ga-68 PSMA-11. Topics will include insight into isotope production, distribution and supply chain, as well as the practical impact on physician practice.



# VIRTUAL EXHIBIT HALL

Meet with top companies at the 2021 SNMMI Mid-Winter and ACNM Annual Meeting and explore the latest technologies and products available in the field.

## CURRENT EXHIBITING COMPANIES INCLUDE:

### **Advanced Accelerator Applications**

8205 B&G Court  
Stokesdale, NC 27357  
Phone: 336.643.2000  
[www.ais-nuclear.com](http://www.ais-nuclear.com)

### **American Board of Nuclear Medicine (ABNM)**

1030 Highlands Plaza Drive, Suite 511E  
St. Louis, MO 63110  
314.367.2225  
[www.abnm.org](http://www.abnm.org)

### **American College of Radiology (ACR)**

1891 Preston White Drive  
Reston, VA 20191  
Phone: 800.227.5463  
[www.acr.org](http://www.acr.org)

### **American Society of Nuclear Cardiology (ASNC)**

9302 Lee Highway  
Suite 1210  
Fairfax, Virginia 22031  
Phone: 703.459.2555  
[www.asnc.org](http://www.asnc.org)

### **Blue Earth Diagnostics**

25 Mall Road, Suite 206  
Burlington, MA 01803  
Phone: 781.494.4100  
[www.blueearthdiagnostics.com](http://www.blueearthdiagnostics.com)

### **Bracco Diagnostics Inc.**

259 Prospect Plains Road,  
Building H  
Monroe Township, NJ 08831  
Phone: 609.514.2200  
<https://cardiogen.com/>

### **Cardinal Health**

7200 Cardinal Place  
Dublin, OH 43017  
Phone: 614.757.5000  
[www.cardinalhealth.com](http://www.cardinalhealth.com)

### **Curium**

111 West Port Plaza, Suite 800  
St. Louis, MO 63146  
[www.curiumpharma.com](http://www.curiumpharma.com)

### **Hermes Medical Solutions**

710 Cromwell Drive, Suite A  
Greenville, NC 27858  
Phone: 252.751.0664  
[www.hermesmedical.com](http://www.hermesmedical.com)

### **IBA SA**

Chemin du Cyclotron, 3  
1348 Louvain la Neuve  
Belgium  
Phone: 0032 10 201 275  
[www.iba-radiopharmasolutions.com](http://www.iba-radiopharmasolutions.com)

### **Intersocietal Accreditation Commission (IAC)**

6021 University Blvd.  
Suite 500  
Ellicott City, MD 21043  
Phone: 800.838.2110  
[www.intersocietal.org](http://www.intersocietal.org)

### **ITM Isotopen Technologien Munchen AG**

Walther von Dyck Strasse 4  
Garching, Bavaria 85748  
Germany  
Phone: +49 89 3298986-155  
[www.itm.ag](http://www.itm.ag)

### **Jubilant Radiopharma**

16751 Transcanada Highway  
Kirkland QC H9H 4J4  
Canada  
Phone: 514.694.8220  
[www.jubilantradiopharma.com](http://www.jubilantradiopharma.com)

# VIRTUAL EXHIBIT HALL

Meet with top companies at the 2021 SNMMI Mid-Winter and ACNM Annual Meeting and explore the latest technologies and products available in the field.

## CURRENT EXHIBITING COMPANIES INCLUDE:

### **Lantheus Holdings**

331 Treble Cove Road  
North Billerica, MA 01862  
Phone: 800.362.2668  
[www.lantheus.com](http://www.lantheus.com)

### **MedImage, Inc.**

331 Metty Drive  
Suite 1  
Ann Arbor, MI 48103  
Phone: 734.665.5400 \*121  
[www.medimage.com](http://www.medimage.com)

### **MIM Software Inc.**

25800 Science Park Drive,  
Suite 180  
Cleveland, OH 44122  
Phone: 216.455.0600  
[www.mimsoftware.com](http://www.mimsoftware.com)

### **NorthStar Medical Radioisotopes, LLC**

1800 Gateway Blvd.  
Beloit, WI 53511  
Phone: 608.313.8000  
[www.northstarnm.com](http://www.northstarnm.com)

### **POINT Biopharma Inc.**

4850 W 78th Street  
Indianapolis, IN 46268  
[www.pointbiopharma.com](http://www.pointbiopharma.com)

### **Siemens Medical Solutions USA**

2501 North Barrington Road  
Hoffman Estates, IL 60192  
Phone: 847.304.7700  
[www.siemens-healthineers.com/en-us/molecular-imaging](http://www.siemens-healthineers.com/en-us/molecular-imaging)

### **SOFIE Co.**

21000 Atlantic Boulevard  
Suite 730  
Dulles, VA 20166  
Phone: 703.787.7900  
[www.sofie.com](http://www.sofie.com)

### **Spectrum Dynamics Medical**

301 N. Cattleman Road,  
Suite 109  
Sarasota, FL 34232  
Phone: 941.928.6922  
[www.spectrum-dynamics.com](http://www.spectrum-dynamics.com)

### **Tema Sinergie S.p.A.**

Via Malpighi 120  
48018 Faenza (RA)  
Italy  
Phone: +39 0546 622663  
[www.temasinergie.com](http://www.temasinergie.com)

### **TTG Imaging Solutions, LLC**

2403 Sidney Street Suite 220  
Pittsburgh, PA 15203  
Phone: 866.682.6331  
[www.ttgimagingolutions.com](http://www.ttgimagingolutions.com)

### **Zionexa**

10475 Crosspoint Boulevard  
Suite 250  
Indianapolis, IN 46256  
Phone: 844.946.6392  
[www.zionexa.com](http://www.zionexa.com)



# We would like to thank our 2021 Virtual SNMMI Mid-Winter and ACNM Annual Meeting Sponsors:

## ► TITLE SPONSOR



## ► GOLD SPONSOR



## ► BRONZE SPONSORS



## ► SATELLITE SYMPOSIA SPONSORS





# A History of Innovation, A Future of Promise

**TechneLite**  
Technetium Tc 99m  
Generator

**Xenon  
Xe 133 Gas**

  
**AZEDRA**  
iobenguane I 131 injection for  
intravenous use

**QUADRAMET**  
(SAMARIUM SM 153 LEXIDRONAM INJECTION) 

**NEUROLITE**  
KIT FOR THE PREPARATION OF TECHNETIUM  
Tc99m BICISATE FOR INJECTION

 **Cardiolite**  
Kit for the Preparation of  
Technetium Tc99m Sestamibi for Injection

**Thallium**  
Thallous Chloride  
TI 201 Injection

**Gallium**  
Gallium Citrate  
Ga 67 Injection

For more information on  
Lantheus Nuclear Products  
contact customer service  
1-800-299-3431

For more information on  
AZEDRA contact the  
AZEDRA Service Connection®  
1-844-293-3721

 **Lantheus  
Holdings**

For full Prescribing Information on each of the Lantheus products, please visit [www.lantheus.com](http://www.lantheus.com)



# The Gold Standard in Medical Imaging

The ACR® is the most trusted resource for your nuclear medicine and PET accreditation. Visit us in the **ACR virtual booth** at the SNMMI Mid-Winter Meeting to learn how to maintain excellence in patient quality and safety through the ACR Nuclear Medicine and PET Accreditation Programs.

## Benefits of ACR Accreditation:

- ✓ Complimentary, expedited review.
- ✓ Easy online application process.
- ✓ One application for all nuclear medicine modules.
- ✓ Imaging review by expert nuclear medicine physicians and medical physicists.

Ask about the  
SNMMI meeting  
discount

Save \$100 off  
each modality  
(excluding mammography)

**Fast | Affordable | Trusted**

[acraccreditation.org](http://acraccreditation.org) | 1-800-770-0145 | 